Anti-platelet Effects of Colchicine in Healthy Volunteers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02140372 |
|
Recruitment Status :
Completed
First Posted : May 16, 2014
Results First Posted : February 23, 2016
Last Update Posted : February 23, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Healthy | Drug: Colchicine | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 10 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Anti-platelet Effects of Colchicine in Healthy Volunteers |
| Study Start Date : | May 2014 |
| Actual Primary Completion Date : | January 2015 |
| Actual Study Completion Date : | January 2015 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Volunteer group
Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
|
Drug: Colchicine
Colchicine 1.2 mg followed by 0.6 mg one hour later
Other Name: Colcrys |
- Monocyte Platelet Aggregate: Baseline [ Time Frame: Baseline ]
- Monocyte Platelet Aggregate: 2 Hours [ Time Frame: 2 Hours ]
- Light Transmission Aggregometry: Baseline [ Time Frame: Baseline ]In response to adenosine diphosphate
- Light Transmission Aggregometry: 2 Hours [ Time Frame: 2 hours ]In response to adenosine diphosphate
- Light Transmission Aggregometry: Baseline [ Time Frame: baseline ]In response to adenosine epinephrine
- Light Transmission Aggregometry: 2 Hours [ Time Frame: 2 hours ]In response to adenosine epinephrine
- Platelet Adhesion: Baseline [ Time Frame: Baseline ]
- Platelet Adhesion: 2 Hours [ Time Frame: 2 hours ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Subjects must be more than 18 years of age
Exclusion Criteria:
1) history of cardiovascular disease, including myocardial infarction, history of percutaneous coronary angioplasty or stent, peripheral vascular disease or stroke; 2) history of myelodysplasia; 3) medications known to affect platelet function, including non-steroidal anti-inflammatory drugs, antihistamines, and selective serotonin reuptake inhibitors, during the 5 days prior to participation; 4) medications known to interact with colchicine; 5) history of intolerance to colchicine; 6) acute or chronic symptoms of diarrhea, nausea, or vomiting within 1 month prior to enrollment; 7) known anemia or hemoglobin <10mg/dL; 8) platelet count <100,000 or > 450,000; 9) creatinine clearance <30cc/minute; 10) any known hemorrhagic diathesis; 11) pregnant; 12) Unable to consent; or 13) Participating in a competing study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02140372
| United States, New York | |
| New York University School of Medicine | |
| New York, New York, United States, 10016 | |
| Principal Investigator: | Binita Shah, MD, MS | NYU SOM |
| Responsible Party: | NYU Langone Health |
| ClinicalTrials.gov Identifier: | NCT02140372 |
| Other Study ID Numbers: |
S13-00747 |
| First Posted: | May 16, 2014 Key Record Dates |
| Results First Posted: | February 23, 2016 |
| Last Update Posted: | February 23, 2016 |
| Last Verified: | January 2016 |
|
colchicine platelet activity neutrophil |
|
Colchicine Gout Suppressants Antirheumatic Agents Tubulin Modulators |
Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |

